A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2004
11/18/2004	US20040229790 Substance having an activity which modulates or inhibits proliferation of AILIM(activation inducible lymphocyte immunomodulatory molecule)-expressing cells or production of a cytokine; for treatment of rheumatoid arthritis, osteoarthritis
11/18/2004	US20040229788 Cell surface molecule mediating cell adhesion and signal transmission
11/18/2004	US20040229779 NOVX nucleic acids and their encoded polypeptides; diagnostic and therapeutic applications in the detection of a variety of diseases with differential expression in normal vs. diseased tissues, e.g., detection of a variety of cancers.
11/18/2004	US20040229772 vaccines which are specific against the class of E. coli that gives rise to antibodies that cross-react with and cross-protect against the more common members of the CS4-CFA/I family
11/18/2004	US20040229339 Comprises neisseria membrane protein for use as tool in generation of vaccine to prevent infection and sepsis in infants
11/18/2004	US20040229336 Using lipo-viro-particles isolated from serum of infected patient to culture, propagate and replicate hepatitis C or hepatitis G virus in culture; genetic vaccines and preventing viral diseases
11/18/2004	US20040229282 Controlling and treating sepsis and thrombosis using immunoglobulin which specifically binds tissue factor and prevents binding by blood coagulation factor; immunotherapy and blood disorders
11/18/2004	US20040229277 Compositions and methods for the diagnosis and treatment of tumor
11/18/2004	US20040229260 Comprises nucleotide sequences coding interleukin-1b converting enzyme ligand for use in diagnosis, prevention and treatment of autoimmune, connective tissue and crohn's diseases
11/18/2004	US20040229232 Compositions and methods for the diagnosis and treatment of tumor
11/18/2004	US20040229218 Using immunoglobulin which binds specifically to hepatitis envelope antigens E1 and E2 to detect viral infection
11/18/2004	US20040229214 Synthetic peptides immunoreactive with Hepatitis A virus antibodies
11/18/2004	US20040228935 Plant extract comprising steroidal glycosides from the genus Trichocaulon or Hoodia produced by solvent extraction
11/18/2004	US20040228919 A non-compressed, fast-dispersing solid dosage form suitable for oromucosal administration; maltodextrin having a dextrose equivalent (DE) of between 1 and 20, sorbitol, and the drug; improved storage stability and mechanical strength
11/18/2004	US20040228881 Compositions and methods for modulating neural sprouting
11/18/2004	US20040228880 Vaccine composition comprising iron phosphate as vaccine adjuvant
11/18/2004	US20040228879 Streptococcus pneumoniae polysaccharide is conjugated to protein or peptide, and RSV antigen with adjuvant which is stimmulator of (cytotoxic T) lymphocytes
11/18/2004	US20040228878 Recombinant infectious laryngotracheitis virus and uses thereof
11/18/2004	US20040228877 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
11/18/2004	US20040228876 Composition and Method for Treating Cancer Using Herpes Virus
11/18/2004	US20040228874 Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
11/18/2004	US20040228873 immunogens/vaccines against mycobactium tuberculosis
11/18/2004	US20040228869 Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
11/18/2004	US20040228868 induces apoptosis in mammalian cancer cells; irinotecan; kits
11/18/2004	US20040228865 Prevention and treatment of amyloidogenic disease
11/18/2004	US20040228863 treating or preventing Crohn's disease by administering cyclosporin or its analog in combination with a tumor necrosis factor antagonist
11/18/2004	US20040228862 Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
11/18/2004	US20040228861 CONTIGUOUS HEAVY AND LIGHT CHAIN SEQUENCES SPANNING COMPLEMENTARITY DETERMINING REGIONS FROM WITHIN FR1 AND/OR CDR1 THROUGH CDR3 AND/OR WITHIN FR4; cytotoxic T-lymphocyte antigen 4 (CTLA-4).
11/18/2004	US20040228860 Antibodies to a tumor-associated surface antigen for delivery of diagnostic and therapeutic agents
11/18/2004	US20040228858 Human monoclonal antibodies to CTLA-4
11/18/2004	US20040228857 administration of a human or humanized antibody expressed and glycosylated in a chinese hamster ovaries (CHO) cell expression system to treat T-cell mediated disorders, autoimmune disorders, cancer and infections; vasculitis, arthritis, lupus, psoriasis, multiple sclerosis, graft versus host disease
11/18/2004	US20040228855 Method for treating symptoms of diabetes
11/18/2004	US20040228850 comprises an enzyme (liver enzymes and mucopolysacoharidases) and an immunogen; kits; rheumatoid arthritis
11/18/2004	US20040228845 Methods of using CD8+/TCR- facilitating cells (FC) for the engraftment of purified hematopoietic stem cells (HSC)
11/18/2004	US20040228842 Compositions and methods for cytomegalovirus treatment
11/18/2004	US20040228841 Replication-competent herpes simplex virus mediates destruction of neoplastic cells
11/18/2004	US20040228840 Vector for integration of heterologous sequences into poxviral genomes
11/18/2004	US20040228836 cancer therapeutic agent comprising a cancer targeting molecule linked to a liver-expressed chemokine (LEC)
11/18/2004	US20040228798 A conjugated drug contains virus-like particle is joined to the antigen by a biotin molecule; bioassay; inhibiting HIV infection, viral infection
11/18/2004	CA2766627A1 Optimized fc variants and methods for their generation
11/18/2004	CA2524799A1 Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
11/18/2004	CA2524626A1 The use of a polypeptide domain of slpi to modulate the tumorigenic and metastatic potential of cancer cells
11/18/2004	CA2524623A1 Immunogenic human tnf alpha analogues with reduced cytotoxicity and methods of their preparation
11/18/2004	CA2524615A1 Immunoglobulin conjugates of autoantigens and their use in the prevention of disease
11/18/2004	CA2524571A1 Alzheimer's disease treatment method comprising a beta-amyloid peptide
11/18/2004	CA2524485A1 Vaccinating against infectious diseases using proteosomes
11/18/2004	CA2524293A1 Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
11/18/2004	CA2524217A1 Compositions for inducing immune responses
11/18/2004	CA2524172A1 Cngh0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses
11/18/2004	CA2523720A1 Synthetic gene encoding human carcinoembryonic antigen and uses thereof
11/18/2004	CA2519953A1 Dna vaccine with dna construct encoding survivin protein, and uses thereof against tumor growth
11/18/2004	CA2519680A1 Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
11/18/2004	CA2504493A1 Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
11/17/2004	EP1477497A1 Humanized immunoglobulins and their production and use
11/17/2004	EP1477495A1 Antigenic fragments of the gp21 envelope protein of human T-Lymphotropic virus HTLV
11/17/2004	EP1477494A1 Subunit respiratory syncytial virus vaccine preparation
11/17/2004	EP1477185A2 Pneumococcal genes, portions thereof, expression products therefrom and uses of such genes, portions and products
11/17/2004	EP1477184A2 Neospora vaccine
11/17/2004	EP1476759A2 Diagnostic method for stroke
11/17/2004	EP1476582A1 Nucleotide sequence coding for a tolc containing a heterologous amino acid sequence
11/17/2004	EP1476558A2 Selection of poultry eimeria strains through extra-intestinal sporozoites
11/17/2004	EP1476555A2 YkuR POLYNUCLEOTIDES AND POLYPEPTIDES
11/17/2004	EP1476548A2 Process of cell electrofusion
11/17/2004	EP1476545A2 Aggrecanase molecules
11/17/2004	EP1476543A1 Viral variants with altered susceptibility to nucleoside analogs and uses thereof
11/17/2004	EP1476541A2 Novel cytokine zcytor17 ligand
11/17/2004	EP1476469A1 MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR
11/17/2004	EP1476468A2 Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity
11/17/2004	EP1476463A1 Mhc class i peptide epitopes from the human 5t4 tumor-associated antigen
11/17/2004	EP1476461A2 Immune-modulating peptide made of s. aureus enterotoxin b
11/17/2004	EP1476456A2 Compositions and methods for surrogate antibody modulation of an immune response and transport
11/17/2004	EP1476454A1 Binding epitopes for helicobacter pylori and use thereof
11/17/2004	EP1476197A2 Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue
11/17/2004	EP1476195A2 Enhancement of the action of central and peripheral nervous system agents
11/17/2004	EP1476188A2 Method for accessing microbial diversity
11/17/2004	EP1476187A2 Methods of extending corneal graft survival
11/17/2004	EP1476186A1 Use of an inhibitor or antagonist against tissue factor
11/17/2004	EP1476185A2 Antibodies to cd40
11/17/2004	EP1476183A1 An immunological adjuvant
11/17/2004	EP1476182A1 Immunogenic formulations of variable peptidic epitopes and process for preparation thereof
11/17/2004	EP1476181A2 Polyalkylene polymer compounds and uses thereof
11/17/2004	EP1476180A2 Interleukin-2 mutants with reduced toxicity
11/17/2004	EP1476177A2 Peptide constructs for treating disease
11/17/2004	EP1476173A1 Outer membrane vesicles from gram negative bacteria and use as a vaccine
11/17/2004	EP1476171A2 Transportation of nucleic acid substances
11/17/2004	EP1476120A2 Treatment methods using anti-cd22 antibodies
11/17/2004	EP1476018A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
11/17/2004	EP1180168B1 MOLECULAR CHARACTERISATION OF CHROMOSOME TRANSLOCATION t(11;18)(q21;q21) AND ITS CORRELATION TO CARCINOGENESIS
11/17/2004	EP1105503B1 ISOLATED AND PURIFIED HUMAN SOLUBLE GUANYLYLCYCLASE ALPHA1/BETA1 (hsGCALPHA1/BETA1)
11/17/2004	EP1090037B1 Divalent antibody fragments conjugated to PEG
11/17/2004	EP1073733B1 MUTATED PEPTIDE COMPOUNDS, DERIVED FROM hsp70, USEFUL IN CANCER IMMUNOTHERAPY
11/17/2004	EP0981369B1 Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
11/17/2004	EP0942928B1 Subunit respiratory syncytial virus vaccine preparation
11/17/2004	EP0832185B1 Cell lines infected with granulocytic ehrlichia, vaccines, diagnostics and methods
11/17/2004	EP0731811B1 Chaperonin 10
11/17/2004	EP0726957B1 RECOMBINANT DNase B DERIVED FROM STREPTOCOCCUS PYOGENES
11/17/2004	CN1547617A Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
11/17/2004	CN1547607A Improved methods for producing oocysts
11/17/2004	CN1547590A Humanized anti-LT-beta-R antibodies
11/17/2004	CN1547588A Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use

1 ... 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 ... 1823